

Public Pension Systems in Texas Senate Committee on State Affairs Brian Guthrie, Executive Director April 4, 2018



TRS Overview

- The Teacher Retirement System manages a \$152 billion trust fund and provides pension and health care benefits. TRS serves 1.5 million active and retired members. One of every 20 Texans is a member of TRS.
- The pension trust fund earned a return of 12.6% for FY 2017. The current assumed rate is 8.0%.
- The Unfunded Actuarial Accrued Liability is \$35.5 billion with a funded ratio of 80.5%. The amortization period is 32.2 years.
- TRS manages two major health programs:
 - TRS-Care for retirees and dependents;
 - TRS-Active Care for active employees and dependents.



Trust Fund Status

TRS Trust Fund Valuation	8/31/2017	8/31/2016	8/31/2015
Unfunded Actuarial Accrued Liability (UAAL)	\$35.5 billion	\$35.5 billion	\$32.9 billion
Funded Ratio	80.5%	79.7%	80.2%
State Contribution Rate	6.8%	6.8%	6.8%
District Contribution Rate (applicable only to districts that do not contribute to Social Security)	1.5%	1.5%	1.5%
Member Contribution Rate	7.7%	7.2%	6.7%
Funding period (years)	32.2 years	33.6 years	33.3 years
Annual Required Contribution (ARC)	7.85%	7.94%	7.92%




TRS Strategic Asset Allocation

RS

	Diversificati	on Framework		Strategic Asset Allocation	
Category Asset Class	Stable Value 16% Treasuries 11% Stable Value Hedge Funds 4% Cash 1% Absolute Return 0%	Global Equity 57% <u>44% Public</u> Equities: USA 18% Non-US Developed 13% Emerging Markets 9% Directional Hedge Funds 4% <u>13% Private Equity</u>	y Real Return 22% Global Inflation-Linked Bonds 3% Real Assets 14% Energy, Natural Resources & Infrastructure 5% Commodities 0% REITS 0%	USA Non-US Developed Emerging Markets Directional Hedge Funds Private Equity Total Global Equity US Treasuries Absolute Return Stable Value Hedge Funds Cash Total Stable Value Global Inflation-Linked Bonds	18% 40% 13% Public 9% Equities 4% 13% 57% 11% 0% 4% 1% 16% 3% 1.4%
		Risk Parity 5%		Real Assets Energy, Natural Resources & Infrastructure	14% 5%
Economic Conditions	•GDP surprises are negative •Inflation surprisingly low with weak demand •Negative earnings surprises •Out of line valuations •Flight to quality	 Positive GDP surprises Inflation surprises not dramatic Positive earnings surprises Reasonable valuations Political stability 	 Real GDP growth too low Inflation surprises on the high side Real earnings too low Commodity-oriented demand exceeds supply by an above normal margin 	Commodities Total Real Return Total Risk Parity	0% 22% 5%
				Total Trust	100%

TRS Performance

Period Ending September 30, 2017¹




- Public Fund Manager of the Year (Institutional Investor) ٠
- **Risk Manager of the Year** ٠
- Numerous "Rising Star" awards by Investor Intelligence •
- US Institutional Risk Premia Manager of the Year Award (2018)

- Three "Top 40 under 40" aiCIO award recipients
- 5-Time LP of the Year (PE and RE) ٠
- "Change Maker of the Year" Award (IIA 2017)
- Top decile Organization Health Study results (2018)



TRS Best Practices



Talent Manager

(Observer)

Risk

Management

Board Responsibilities

- Establish investment objectives and policy (IPS- The Investment Policy Statement provides a formal plan for investing pension trust fund and health insurance program assets)
- Approve long-term return targets and risk parameters
- Provide appropriate resources, incentives and establish approved processes
- Establish appropriate reporting standards and metrics
- · Comply with relevant laws and assure professional audit systems
- Approve budget
- Review IIC investment considerations prior to IIC Action

IIC Responsibilities

- Review, consider, and authorize proposed external manager investments and engagements as required by the IPS
- ED is non voting member but has power to veto any investment or delegation

MC Responsibilities


- Advise CIO/DCIO
- Review and attribute monthly performance reporting
- Monitor risk exposures, market performance and future expectations
- Track and report Trust and group priorities

IMD Responsibilities

- Implement investment policies within approved guidelines
- Maximize effectiveness of resources provided
- Deliver monthly Transparency Report to Board
- Comply with relevant laws
- Collaborate with audit process
- Implement Board objectives



TRS Best Practices



Note: Limit on IIC Authority for a First-time investment with a manager is 0.5%; Add-on Allocations are 1%

Independent Reviews

More than **80** audits and reports over the last 6 years covering all major functions of the investment management division of TRS. No significant findings.

Function	# of Audits	Auditors
Operations	27	Internal, SAO, Comptroller, Grant Thronton, German Tax Authority
Performance	8	Internal, SAO
Policy	27	Internal, SAO
Risk Management	6	Internal
Trading	3	Internal
Legislative Authority		
Derivatives	3	Internal
Hedge Funds	2	Internal
External Management	12	Internal, Funston
Total	88	




Financial Disclosure & Transparency

Comprehensive Annual Financial Report

- $\,\circ\,$ All TRS returns are reported net of fees and expenses.
- $\circ~$ Fees disclosed by the following by asset class:
 - Assets Under Management
 - Fees paid from trust (management and performance)
 - Fees netted with returns (management and performance).
- $\,\circ\,$ Disclosures consistent with GASB and GFOA guidance.

GASB: Governmental Accounting Standards Board GFOA: Governmental Finance Officers Association



The amount of fees paid from the pension trust fund and booked as expenses in Table 6 are for the calendar year ended June 30, 2017. The amount of fees paid from the pension trust fund and booked as expenses for the fiscal year ended August 31, 2017, which appear in Exhibit II and Schedule 2 as External Manager Fees, amounted to \$126,449,587, which includes \$83,925,746 in management fees and \$42,523,841 in performance fees.



Actuarial Assumptions

- Section 825.206, Government Code requires the TRS Board of Trustees to designate an actuary to conduct an experience study to review all actuarial assumptions. An actuarial audit must be performed in conjunction with the experience study at least once every five years.
- Previous experience study conducted and assumptions set in 2015.
- In determining liabilities and contribution rates for retirement plans, actuaries must make assumptions about the future. Among the assumptions that must be made include: retirement rates, mortality rates, turnover rates, disability rates, investment return rate, salary increase rates, inflation rate.
- Board considers the actuary's study and recommendations. Board must demonstrate fiduciary duty of loyalty- independence from the plan sponsor, contributing employers or other outside influences. Each Trustee acts for the benefit of the trust as a whole, not for or on behalf of an individual member, a group of members, or any other third party.



AON Analysis of Investment Return Rate

Asset Class	Long-Term Target Asset Allocation	10 Year Expected Geometric Rate of Return	30 Year Expected Geometric Rate of Return
(1)	(2)	(3)	(4)
U.S. Equity	18%	6.4%	6.5%
Non-US Developed	13%	7.2%	7.2%
Emerging Markets	9%	7.6%	7.7%
Directional Hedge Funds	4%	5.2%	5.7%
Private Equity	13%	9.1%	9.4%
U.S. Treasuries	11%	3.0%	3.2%
Stable Value Hedge Funds	4%	5.1%	5.6%
Cash	1%	2.0%	2.6%
Global Inflation Linked Bonds	3%	2.9%	3.4%
Real Assets	14%	6.4%	6.4%
Energy and Natural Resources	5%	8.5%	8.5%
Risk Parity	5%	<u>5.5%</u>	<u>5.5%</u>
Gross Expected Return		7.14%	7.34%
Probability of Achieving:			
8.00%		<mark>41.4%</mark>	<mark>38.8%</mark>
7.50%		<mark>46.4%</mark>	<mark>47.3%</mark>
7.25%		<mark>48.9%</mark>	<mark>51.6%</mark>
7.00%		<mark>51.4%</mark>	<mark>55.9%</mark>



GRS Range of Options

	Current Assumptions	Proposed Assumptions	Proposed Assumptions	Proposed Assumptions
	(1)	(2)	(3)	(4)
Investment Return Assumption	8.00%	7.50%*	7.25%	7.00%
UAAL (\$ Billions)	\$35.5	\$42.8	\$45.9	\$51.7
Actuarial Funded Ratio	80.5%	77.4%	76.1%	73.9%
Funding Period in years based on current funding levels	33	60	86	NA
Immediate increase in Contribution Rate needed to have 30 year funding period	0.15%	1.38%	1.82%	3.05%
Additional Estimated FY18 Contributions	\$65m	\$599m	\$786m	\$1,323m
Funding Period with 1.5% additional contributions beginning in FY20	19	29	35	54
Funding Period with 2.0% additional contributions beginning in FY20	17	26	31	42

Funding periods are calculated as of 8/31/2017. Changes to the valuation date or the date the contributions become effective will result in slightly different outcomes. *Inflation held at 2.5%



Experience Study

Why is the investment return assumption being discussed?

TRS is required by law to conduct an experience study at least once every five years. The purpose of an experience study is to determine if actual behavior, plan provisions, and investment returns have matched assumptions, or if adjustments are necessary. Significant changes in the global economic outlook over the last three years warranted examining TRS' experience sooner than the five year deadline. The experience study determined that while most of the assumptions were accurate, the investment return assumption needed to be adjusted. The TRS Board of Trustees will consider lowering the current 8.0% investment return assumption in April. This action will not change TRS' strategic asset allocation.

When and where will the TRS Board of Trustees discuss this issue?

The Board will meet on April 20, 2018 to discuss the issue. For those unable to travel to Austin, TRS webcasts all board meetings live. Viewers may watch the event live from a computer or smartphone with internet connection wherever they are. In addition, the live webcasts are recorded and archived in the Board of Trustees section for on-demand viewing. Visit the TRS website for more information on webcasts.

Will my monthly annuity payment be reduced if the rate is changed?

No. The Board of Trustees does not have the authority to change annuity benefit payments for current and future retirees. Only the Legislature can make annuity benefit changes.



If the TRS Board of Trustees lowers the investment return assumption in April, TRS will request a contribution rate increase in the upcoming legislative session. Only the Legislature has the authority to set contribution rates.

Current Contribution Rates



Economic Outlooks

TRS examined 11 different economic outlooks from nine independent investment advisors. The data showed the average expected return ranged from 7.07% - 7.32%.




Pension Benefit Design Study

- In 2011, TRS was directed by the Legislature to conduct a study on the impacts of potential changes to its current defined benefit pension plan. TRS completed and submitted the study on September 1, 2012. In 2013, pension legislation (SB 1458) provided benefit changes and SB 1 increased funding.
- TRS is updating the study to reflect current and expected market conditions, refresh data on the economic value of a defined benefit plan, and examine other plan options.



83R-SB 1458 and SB 1





Implementation of HB 3976: TRS-Care Senate Committee on State Affairs Brian Guthrie, Executive Director April 4, 2018



Challenges for TRS-Care


- Long-term funding based on percentages of active employee payroll and not health care costs for retirees.
- At the direction of the legislature, retiree premiums and plan designs were frozen from 2005-2017.
- During the 85th legislature, the shortfall was projected to be from \$1.06 to \$1.3 billion. The following biennium shortfall was expected to range from \$4 to \$6 billion.
- Even with legislative changes, the current structure for TRS-Care is not sustainable.
- Major plan design and/or funding changes had to occur in the 85th Legislative Session.
- Approximately 20,000 new retirees are added to the plan each year.
- Non-Medicare retirees cost up to four times more than the cost of Medicare-eligible participants.
- FY 2016, each non-Medicare eligible participant in TRS-Care 3 cost the plan approximately \$13,700 versus \$3,222 for a retiree enrolled in Medicare Advantage and Medicare Part D plans.

Without legislative changes and additional funding, the program would have become unsustainable.


FY 20/21 shortfall is projected to be \$400-\$600 million.



2018 TRS-Care Implementation Overview



Unprecedented Call Volume



Mitigations and Remediation of Issues



APPLIED

more resources to handle call volume, process disenrollments. Contracted with ACT



COORDINATION

with CMS to ensure terminations (Medicare population)

• Worked with CMS to review populations.



INCREASED speed on file transfers to vendors

- TRS sent files every other working business day between December 14 - 22.
- Between December 12 29, TRS sent enrollment files each day.
- TRS sent files to vendors again on January 3, 5 and 8.



FLEXIBILITY

accommodated requests outside of normal timeframes

Example: Permitting coverage to be retroactively terminated back to January 1, 2018.



CONTINUING

to review data post-migration


- Data conditioning.
- Long-term to apply lessons to TRS systems



TRS-Care Funding Projection

Projected Fund Balance as of August 31, 2017

(Incurred Basis in Millions)



current trend levels by 2 percentage points.



85th Legislative Session

<u>HB 3976</u>

- Single, high deductible health plan for non-Medicare participants
- Medicare Advantage and Medicare Part D plan for Medicare participants
- Increase the required State contribution from 1% to 1.25% of active employee payroll
- Eliminate the requirement that TRS offer a basic plan at no cost for Retiree Only coverage
- \$0 retiree contribution for disability retirees who are: (1) retired as a disability retiree on or before 1/1/2017; (2) currently receiving disability retirement benefits; and (3) not eligible to enroll in Medicare.
- Provide an open enrollment opportunity for retirees aging into Medicare to enroll in the TRS-Care Medicare plan even if he/she did not participate in TRS-Care's non-Medicare plan.
- Provide no-cost coverage for certain generic preventive drugs.

<u>SB 1</u>

- Increase the required State contribution from 1% to 1.25% of active employee payroll
- Increase the required District contribution from 0.55% to 0.75% of active employee payroll
- Provide supplemental State funding of \$182.6M
- Eliminate legislative intent to not increase retiree premium contributions



85th-1 Special Session

<u>**HB 21 and HB 30:</u>** Appropriation of \$212 million to provide relief to every participant in TRS-Care. Legislative intent to reduce TRS-Care Standard plan deductible from \$3,000 to \$1,500 and reduce dependents premiums for both plans.</u>

Total Additional one-time /New Funding						
+ \$167.4M	(0.25% state contribution increase)					
+ \$182.6M	(<u>one-time</u> supplemental contribution)					
+ \$133.9M	(0.20% district contribution increase)					
+ \$212.0M	(85-1 <u>one-time</u> supplemental contribution)					
= \$695.9M						



Comparison: Premiums

Previous Premiums	85R Legislature Illustrative Retiree Premiums	85-1 Legislature/Board Adopted Final Premiums
Prior to January 1, 2018	Calendar Year 2018	Calendar Year 2018
$\frac{\text{Non-Medicare Retirees}}{\text{Retiree Only} = \$0 - \$310}$ Retiree & Spouse = \$30 - \$665 Retiree & Child(ren) = \$28 - 392 Retiree & Family = \$58 - \$747 $\frac{\text{Medicare B Only Retirees}}{\text{Retiree Only} = \$0 - $245}$ Retiree & Spouse = \$25 - \$600 Retiree & Child(ren) = \$34 - \$327 Retiree & Family = \$59 - \$682 $\frac{\text{Medicare A\&B Retirees}}{\text{Retiree Only} = \$0 - $110}$ Retiree & Spouse = \$20 - \$465 Retiree & Spouse = \$20 - \$465 Retiree & Child(ren) = \$41 - \$192 Retiree & Family = \$61 - \$547	Non-Medicare Retirees Retiree Only = \$200 Retiree & Spouse = \$739 Retiree & Child(ren) = \$433 Retiree & Family = \$1,074 <u>Medicare Retirees</u> Retiree Only = \$146 Retiree & Spouse = \$590 Retiree & Child(ren) = \$504 Retiree & Family = \$1,106 <u>Current Disability Retirees</u> not eligible for Medicare* Retiree Only = \$0 Retiree & Spouse = \$539 Retiree & Child(ren) = \$233 Retiree & Family = \$874	Non-Medicare Retirees Retiree Only = \$200 Retiree & Spouse = \$689 Retiree & Child(ren) = \$408 Retiree & Family = \$999 Medicare Retirees Retiree & Spouse = \$529 Retiree & Spouse = \$529 Retiree & Spouse = \$529 Retiree & Family = \$1,020 Current Disability Retirees not eligible for Medicare* Retiree & Spouse = \$489 Retiree & Spouse = \$489 Retiree & Child(ren) = \$208 Retiree & Family = \$799 Retirees with adult disabled children Non-Medicare Retiree & Child(ren) = \$208 Non-Medicare Retiree & Child(ren) = \$208 Non-Medicare Retiree & Child(ren) = \$208 Retiree & Family = \$799

*Applies to members who retired as a disability retiree as of 1/1/2017



Comparison: Medical Plan Design

	TRS-Care 1	TRS-Care 2	TRS-Care 3	Medicare Advantage for TRS-Care 2	Medicare Advantage for TRS- Care 3	85R-Legislature Standard Plan	85R-Legislature Medicare Advantage Plan	85-1 Legislature / Board Adopted Final Standard Plan	85-1 Legislature/ Board Adopted Final Medicare Advantage Plan
Eligibility		All retirees		Retirees with b Part A		Non-Medicare Retirees (under age 65)	All Medicare Retirees (age 65 and older)	Non-Medicare Retirees (under age 65)	All Medicare Retirees (age 65 and older)
Deductible In- Network	\$2,350 Parts A&B \$3,900 Part B Only \$5,250 Non-Medicare	\$1,300	\$400	\$500	\$150	\$3,000 individual \$6,000 family	\$500	\$1,500 individual \$3,000 family	\$500
Maximum Out-of- Pocket In-Network	\$6,250 Parts A&B \$7,800 Part B Only \$8,250 Non-Medicare	\$5,800	\$4,900	\$3,500	\$3,150	\$6,650 individual \$13,300 family	\$3,500	\$5,650 individual \$11,300 family	\$3,500
Coinsurance				95%/5%	95%/5%		95%/5%		95%/5%
Inpatient Hospital Facility	80%/20%	80%/20%	80%/20%	\$500 copay per stay	\$250 copay per stay	80%/20% (after deductible is met)	\$500 copay per stay	80%/20% (after deductible is met)	\$500 copay per stay
Outpatient Hospital Facility	(after deductible is met)	(after deductible is met)	(after deductible is met)	\$250 copay	\$75 copay	Preventative services such routine physical exam, cancer		Preventative services such routine physical exam, cancer	\$250 copay
Emergency Room	Preventative			\$65 copay	\$50 copay	screenings, flu shot covered at 100%	\$65 copay	screenings, flu shot covered at 100%	\$65 copay
Urgent Care	services such routine physical			\$35 copay	\$35 copay	\$40 Teladoc consultation:	\$35 copay	\$40 Teladoc consultation:	\$35 copay
Office Visits	screenings, flu Non-Med shot covered at \$35 cop 100% Medica 80%/20% Medica	Non-Medicare: \$35 copay Medicare: 80%/20% (after Medicare payment)	Non-Medicare: \$25 copay Medicare: 80%/20% (after Medicare payment)	\$5 Primary Care Physician \$10 Specialist	\$5 Primary Care Physician \$10 Specialist	Board-certified doctors diagnose, treat and write prescriptions via phone or video, available 24/7	\$5 Primary Care Physician \$10 Specialist	Board-certified doctors	\$5 Primary Care Physician \$10 Specialist



Comparison: Prescription Plan Design

	TRS-Care 1	TRS-Care 2	TRS-Care 3	Medicare Part D for TRS-Care 2	Medicare Part D for TRS-Care 3	1/1/2018 85-R Legislature / Board Adopted Standard Plan	1/1/2018 85-R Legislature / Board Adopted Medicare Advantage Plan
Eligibility		All retirees		Retirees v Medicare	vith either Part A or B	Non-Medicare retirees (under age 65)	All Medicare retirees (age 65 and older)
Retail Copays							
Generic	80%/20% (after deductible is met)	\$10	\$10	\$5	\$5	Preventative Maintenance \$0 80%/20% (after deductible is met)	\$5
Preferred Brand	80%/20% (after deductible is met)	\$30	\$25	\$25	\$20	80%/20% (after deductible is met)	\$25
Non-Preferred Brand		\$50	\$40	\$50	\$40	80%/20% (after deductible is met)	\$50
Mail Order Copays							
Generic	80%/20% (after deductible is met)	\$20	\$20	\$15	\$15	80%/20% (after deductible is met)	\$15
Preferred Brand	80%/20% (after deductible is met)	\$75	\$50	\$70	\$45	80%/20% (after deductible is met)	\$70
Non-Preferred Brand	80%/20% (after deductible is met)	\$125	\$80	\$125	\$80	80%/20% (after deductible is met)	\$125



TRS-Care Standard Prescription Drug Plan

The 85th-R Legislature appropriated funds to provide certain generic preventive drugs at no cost to the participant allowed under federal law.

High Deductible Health Plan (HDHP) - Health Savings Account (HSA)

Generics Only Preventive Therapy Drug List

(09/01/17)

ANTICOAGULANTS/ ANTIPLATELETS ANTICOAGULANTS enoxaparin fondaparinux warfarin Jantoven

PLATELET AGGREGATION INHIBITORS clopidogrel dipyridamole

dipyridamole ext-rel/aspirin ANTICONVULSANTS carbamazepine carbamazepine ext-rel clonazepam divalproex sodium delaved-re divalproex sodium ext-rel ethosuximide felhamate lamotriaine lamotrigine ext-rel levetiracetam levetiracetam ext-rel oxcarbazenine nhenoharhital phenytoin phenytoin sodium extended primidone tiagabine topiramate topiramate ext-rel valproic acid zonisamide Epitol

CARDIOVASCULAR CONDITIONS

OTHER ANTIARRHYTHMIC AGENTS amiodarone disopvramide dofetilide flecainide propafenone propafenone ext-rel sotalol sotalol AF Pacerone ORAL ANTIANGINAL AGENTS

isosorbide dinitrate isosorhide dinitrate ext_rel

isosorbide mononitrate isosorbide mononitrate ext-rel SL and chewable formulations are not included on this list TRANSDERMAL/TOPICAL ANTIANGINAL AGENTS

nitroglycerin transderma Minitran CORONARY ARTERY DISEASE ANTIHYPERLIPIDEMICS atorvastatin

cholestyramine

colestipol

ezetimibe

fenofibrate

fluvastatin

aemfibrozil

niacin ext-re

rosuvastatin

DIABETES

acarbose

alogliptin

chlorpropamide

glipizide ext-rel

alipizide/metformin

alvburide, micronized

alvburide/metformin

metformin ext-rel

alimepiride

alipizide

alvburide

metformin

simvastatin

Niacor

Prevalite

lovastatin

pravastatin

fenofibric acid

fluvastatin ext-rel

benazepril benazepril/hvdrochlorothiazide candesartan candesartan/hydrochlorothiazide captopril captopril/hydrochlorothiazide fenofibric acid delaved-re ramipril valsartan

COMBINATION ANTIHYPERI IPIDEMICS amlodipine/atorvastatir ezetimibe/simvastatin Over-the-Counter (OTC) products require a prescription Coverage may vary by plan. ORAL DIABETES AGENTS alogliptin/metformin alogliptin/pioglitazone

repaglinide/metformin tolbutamide HYPERTENSION ACE INHIBITORS/ANGIOTENSIN II RECEPTOR ANTAGONISTS AND COMBINATION AGENTS amlodipine/benazepril

miglitol

nateglinide

pioglitazone

repaglinide

pioglitazone/glimepiride

pioglitazone/metformin

enalapril enalapril/hydrochlorothiazide eprosartan fosinopril fosinopril/hydrochlorothiazide irbesartan irbesartan/hydrochlorothiazide lisinopril lisinopril/hydrochlorothiazide losartan losartan/hvdrochlorothiazide moexipril moexipril/hydrochlorothiazid olmesartan olmesartan/hvdrochlorothiazide perindopril auinapril guinapril/hvdrochlorothiazide telmisartar telmisartan/hydrochlorothiazide trandolapril trandolapril/verapamil ext-rel

valsartan/hvdrochlorothiazide BETA-BLOCKERS AND COMBINATION AGENTS acebutolol atenolol

atenolol/chlorthalidone betaxolol bisoprolol bisoprolol/hydrochlorothiazide carvedilol labetalol

metoprolol metoprolol succinate ext-rel metoprolol/hydrochlorothiazide nadolol nadolol/bendroflumethiazide pindolol propranolol propranolol ext-rel propranolol/hydrochlorothiazide timolol maleate

CALCIUM CHANNEL BLOCKERS AND

COMBINATION AGENTS amlodipine diltiazem diltiazem ext-rel diltiazem XR felodipine ext-rel isradipine nicardipine nifedinine nifedinine ext-rel nisoldinine ext-rel verapamil verapamil ext-rel Afeditab CR Cartia XT Dilt-XR Matzim LA Nifediac CC Taztia XT DIURETICS chlorothiazide indapamide

amiloride/hydrochlorothiazide chlorthalidone hydrochlorothiazide methyclothiazide spironolactone/hydrochlorothiazide triamterene/hydrochlorothiazide OTHER ANTIHYPERTENSIVE AGENTS amlodipine/olmesartan

amlodipine/telmisartan amlodipine/valsartan/ hydrochlorothiazide clonidine clonidine transderma guanabenz quanfacine hydralazine methyldopa methyldopa/hydrochlorothiazide minoxidil olmesartan/amlodipine hydrochlorothiazide Clorpres

MENTAL HEALTH ANTIDEPRESSANTS amitriptvline amoxapine

bupropion

citalopram

clomipramine

desipramine

escitalopram

fluovetine

fluvoxamine

maprotiline

mirtazapine

nortriptyline

phenelzine

protriptyline

tranylcypromine

venlafaxine ext-rel

ANTIPSYCHOTICS

aripiprazole

fluphenazin

haloperidol

olanzapine

paliperidone

perphenazine

quetiapine ext-re

auetiapine

risperidone

thioridazine

thiothixene

trifluoperazine

fluvoxamine ext-rel

OSTEOPOROSIS

calcitonin/salmor

ziprasidone

alendronate

ibandronate

calcitonin

loxapine

clozapine

chlomromazine

fluphenazine decanoate

olanzapine orally disintegrating tabs

OBSESSIVE COMPULSIVE DISORDER

sertraline

trazodone

trimipramine

venlafaxine

Irenka

paroxetine HC

imipramine HC

doxepin

bupropion ext-rel

desvenlafaxine ext-re

duloxetine delaved-rel

fluovetine delaved-re

imipramine pamoat

paroxetine HCI ext-rel

PREVENTIVE CARE SERVICES AGENTS FOR CHEMICAL DEPENDENCY acamprosate calcium

zoledronic acid 5 mg/100 mL

raloxifene

risedronate

buprenorphine sublingual buprenorphine/naloxone sublingual disulfiram naltrexone Depade

ANTLOBESITY AGENTS benzphetamine

diethylomonion diethvlpropion ext-rel phendimetrazine phendimetrazine ext-rel phentermine

BOWEL PREPARATIONS peg 3350/electrolytes Gavilyte

SMOKING DETERRENTS bupropion ext-rel nicotine polacriles nicotine transderma

Over-the-Counter (OTC) products require a prescription. Coverage may vary by plan

RESPIRATORY DISORDERS RESPIRATORY AGENTS

budesonide suspension cromolyn sodium nebulizer solution fluticasone/salmeterol montelukast zafirlukast

WOMEN'S HEALTH

AROMATASE INHIBITORS

ANTIESTROGENS

tamoxifen

anastrozole

exemestane

letrozole

zileuton ext-re VARIOUS CONDITIONS ANTI-MALARIAL AGENTS atovaguone/proguanil chloroquine mefloquine

DENTAL CARIES PREVENTION sodium fluoride

IMMUNOSUPPRESSIVE AGENTS

cyclosporine caps mycophenolate mofetil mycophenolate sodium delayed-rel sirolimu tacrolimus Gengraf

MULTIPLE SCLEROSIS AGENTS glatirame

Find the list online at: http://info.caremark.com/ trscarestandard

CONTRACEPTIVES CONTRACEPTIVES - ALL GENERIC PRESCRIPTION FORMULATIONS

PRENATAL VITAMINS PRENATAL VITAMINS - ALL GENERIC PRESCRIPTION PRODUCTS

Over-the-Counter (OTC) emergency contracective product equire a prescription. Coverage may vary by pla

